Changing the future of healthcare through regenerative medicine and drug discovery
Combined strengths, high expectations
T-CiRA is a joint research program by the Center for iPS Cell Research and Application (CiRA), Kyoto University and Takeda Pharmaceutical Company Limited. Over a 10-year period and under the direction of CiRA, this joint program will conduct research to develop clinical applications of iPS cells.
Takeda supports the research of innovative therapies for rare diseases. NGLY1 deficiency is currently being studied under the Takeda-Center for iPS Cell Research and Applications (T-CiRA) program in partnership with RIKEN.
Watch Grace’s story to see how the hard work of many has the potential to impact the lives of those living with this ultra-rare disease.
This video is for disease awareness purposes only.
The T-CiRA research laboratory has been established at the Shonan Health Innovation Park